PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL

✍ Scribed by S Stefani; MG Saggia; EA Santos

• Book ID: 119596051
• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 74 KB
• Volume: 10
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/s1098-3015(10)65190-x